← Back to Search

1 for Cardiovascular Disease (ICA-CHAMP Trial)

N/A
Waitlist Available
Led By Charlotte - Jones, PhD, MD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights

ICA-CHAMP Trial Summary

Research has shown that the presence of heart disease and stroke is higher in the Indo-Asian population compared to other ethno-cultural groups. This may be due to multiple reasons such as a higher presence of diabetes, high blood pressure, high cholesterol, obesity, and lower levels of physical activity. This program will bring together the Calgary Indo-Central-Asian communities and the Calgary Healthcare community to help reduce the rate of heart disease and stroke through a supportive, culturally-sensitive program that is community-based through the following steps: Increase awareness of heart disease and stroke through education among the Calgary Indo-Central-Asian population. Identify early, the risk factors related to heart disease and stroke through screening programs. Provide appropriate follow-up care to the population at risk for heart disease and stroke.

Eligible Conditions
  • Cardiovascular Disease
  • High Cholesterol
  • High Blood Pressure

ICA-CHAMP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Baseline and one year change in blood pressure and total cholesterol, HDL cholesterol and TC/HDL ratio (High and low to moderate risk program participants)
Secondary outcome measures
"No-show" rates at High Risk Assessment clinics and Calgary Health Region Multicultural education program vs. historical rates.
Baseline profiles of attendees versus no-shows at both High Risk Assessment clinics and Calgary Health Region Multicultural education programs
Cardiovascular risk profile and risk scores (Joint British Societies Cardiovascular Disease Risk Prediction Chart) of all participants at baseline and upon completion of the High Risk Assessment and Calgary Health Region Multicultural education programs.
+4 more

ICA-CHAMP Trial Design

2Treatment groups
Experimental Treatment
Group I: 2Experimental Treatment1 Intervention
low to moderate risk
Group II: 1Experimental Treatment1 Intervention
high risk

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
792 Previous Clinical Trials
868,779 Total Patients Enrolled
PfizerIndustry Sponsor
4,570 Previous Clinical Trials
10,915,611 Total Patients Enrolled
Charlotte - Jones, PhD, MDPrincipal InvestigatorUniversity of Calgary

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
ICA-CHAMP: Indo-Central Asian Cardiovascular Health Assessment and Management Program
2007. "ICA-CHAMP: Indo-Central Asian Cardiovascular Health Assessment and Management Program". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00627159.
All > Health > Cardiovascular
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top